## 510(k) Summary

**Date Prepared** 

March 30, 2012

Submitter

Medtronic, Inc.

Medtronic Perfusion Systems

7611 Northland Drive Minneapolis, MN 55428

Establishment Registration Number: 2184009

**Contact Person** 

**Emily Blus** 

Regulatory Affairs Operations Specialist

8200 Coral Sea Street NE Mounds View, MN 55433 Phone: (763) 514-9853 Fax: (763) 367-836

Email: emily.blus@medtronic.com

**Alternate Contact:** 

Susan Fidler

Senior Regulatory Affairs Manager Medtronic Perfusion Systems

Phone: 763.514.9839 Fax: 763.367.8360

Email: susan.c.filder@medtronic.com

### **Device Name and Classification**

Trade Name:

DLP® Silicone Single Stage Venous Cannula with Inflatable Cuff

Common Name:

Cardiopulmonary bypass vascular catheter, cannula, or tubing

Regulation Number:

21 CFR 870.4210

**Product Code:** 

DWF

Classification:

Class II

**Predicate Device** 

K854487

Venous Return Cannula with Cuff

### **Device Description**

The DLP® Silicone Single Stage Venous Cannula with Inflatable Cuff is used during cardiopulmonary bypass surgical procedures for collecting and directing blood from the right side of the heart via the superior and inferior vena cava into the bypass circuit. These cannulae are comprised of a wire-wound, kink-resistant silicone cannula body with a nominal tip outer diameter of 37Fr and an overall length of 15 inches. The DLP® Silicone Single Stage Venous Cannula with Inflatable Cuff model features a manually inflatable silicone inflatable cuff near the distal tip of the device which, once inflated, assists in maintaining the position of the device throughout the cardiopulmonary bypass procedure.

#### **Indications for Use**

These cannulae are intended for collection of venous blood from the right side of the heart via the superior and inferior vena cava during cardiopulmonary bypass surgery up to six hours or less.

#### **Contraindications**

This device is contraindicated for long-term use. Do not use for extended terms such as Ventricular Assist procedures.

### **Comparison to Predicate Device**

A comparison of the modified device to the currently marketed DLP® Silicone Single Stage Venous Cannula with Inflatable Cuff notes the following similarities:

- · Same intended use
- Same operating principle
- Same technological characteristics
- Same design features
- · Same shelf life

#### Conclusion

Medtronic has demonstrated that the modifications to the DLP® Silicone Single Stage Venous Cannula with Inflatable Cuff described in this submission result in a substantially equivalent device because the fundamental scientific technology, the intended use, operating principle and design features are unchanged since the predicate device. Any noted differences do not raise new issues of safety and effectiveness.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

JUN - 6 2012

Medtronic, Inc. c/o Ms. Jacqueline A. Hauge Regulatory Affairs Specialist 8200 Coral Sea Street NE Mounds View, MN 55112

Re: K120987

Trade/Device Name: DLP Silicone Single Stage Venous Cannula with Inflatable Cuff

Regulation Number: 21 CFR 870.4210

Regulation Name: Cardiopulmonary bypass vascular catheter, cannula, or tubing

Regulatory Class: Class II Product Code: DWF

Dated: May 10, 2012 Received: May 11, 2012

### Dear Ms. Hauge:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be

### Page 2 - Ms. Jacqueline A. Hauge

found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

& Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

W & Hillelen

Center for Devices and

Radiological Health

Enclosure

# **Indications for Use**

510(k) Number (if known): K120987

| Device Name:                        | Device Name: DLP® Silicone Single Stage Venous Cannula with Inflatable Cuff |                           |                             |               |        |  |
|-------------------------------------|---|---------------------------|-----------------------------|---------------|--------|--|
| Indications For U                   | Jse:  |                           |                             |               | ,      |  |
|                                     | are intended for coll<br>inferior vena cava o                               |                           |                             |               |        |  |
|                                     |   |                           |                             |               |        |  |
|                                     |   | •                         |                             | -             |        |  |
|                                     |   |                           |                             |               | •      |  |
|                                     |   |                           |                             | ٠.            |        |  |
|                                     |   |                           |                             |               |        |  |
|                                     |   | •                         |                             |               |        |  |
|                                     |   |                           |                             |               |        |  |
| •                                   |   |                           |                             |               |        |  |
|                                     |   |                           |                             | **            |        |  |
| Prescription Use<br>(Part 21 CFR 80 |   | AND/OR                    | Over-The-Cou<br>(21 CFR 807 |               | _      |  |
| (PLEASE DO N                        | OT WRITE BELO   | W LINE-CONTIN             | IUE ON ANOTHE               | ER PAGE IF NI | EEDED) |  |
|                                     | Concurrence of (  | CDRH, Office of D         | Device Evaluation (         | (ODE)         | · .    |  |
|                                     | Page  | 1 of <u>1</u>             | -                           |               |        |  |
|                                     | (Division Sign-Control of Care  | Off)<br>diovascular Devid | ces                         |               |        |  |
|                                     | 510(k) Number   | k120987                   |                             |               |        |  |